Key Takeaways

From the Authors As published in the article
  1. Approximately half of patients with major depressive disorder (MDD) have inadequate response to antidepressant therapy (ADT).
  2. In this 6-week randomized controlled trial, lumateperone 42 mg adjunctive to ADT significantly improved depression symptoms and disease severity in patients with MDD and inadequate response to 1 or 2 ADTs.
  3. Adjunctive lumateperone 42 mg was generally well tolerated with low risk of motor symptoms, weight gain, cardiometabolic effects, or hyperprolactinemia.
Extended Takeaways
  1. Improvement emerged early: the discussion notes clinically meaningful, significant benefits by day 8 that persisted through day 43, which may matter when augmentation is being considered for symptomatic patients who cannot wait 6–12 weeks for additional benefit.
  2. The antidepressant signal was sizable for an adjunctive antipsychotic trial, with MADRS change at day 43 showing LSMD vs placebo=−4.9; 95% CI, −6.38 to −3.44; effect size [ES]=−0.61; P <.0001, alongside CGI-S improvement of LSMD=−0.7; 95% CI, −0.85 to −0.48; ES =−0.67; P <.0001.
  3. Potential utility extended to clinically harder-to-treat presentations: nearly half of participants met DSM-5 anxious distress criteria at baseline (placebo + ADT, n=99 [40.7%]; lumateperone + ADT, n=110 [45.6%]), and lumateperone + ADT significantly improved both MADRS Total score and CGI-S score in this subgroup.
  4. Tolerability should be weighed against a higher overall TEAE burden with active treatment, occurring in 58.1% with lumateperone + ADT versus 46.5% with placebo + ADT; however, most TEAEs (>98%) were mild or moderate, and discontinuation due to TEAEs remained limited.
  5. If tremor occurs, the study suggests it is usually early and manageable: tremor was reported in 12 patients on lumateperone + ADT versus 1 on placebo + ADT, most cases began during the first 2 weeks, mean (SD) duration was 14.6 days (±10.65 days), and only 1 patient discontinued because of tremor.
  6. For patients in whom suicidality or QT liability are active prescribing concerns, no suicidal behavior occurred during treatment, emergence of suicidal ideation was 1.4% with lumateperone+ADT versus 3.5% with placebo+ADT, and no lumateperone-treated patients had QT Fridericia-corrected interval ≥480 ms or an increase of >60 ms from baseline.
Read full article
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen to the JCP Podcast Now
Figure: Digital illustration shows a human head with neural connections and podcast title over a dark blue patterned background.

Subscribe to read
more articles

Subscribe